[{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-aminobutyric acid receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-10; Voltage-dependent L-type calcium channel subunit alpha-1C; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-3; Glutamate receptor 1; Voltage-dependent calcium channel gamma-1 subunit; Neuronal acetylcholine receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-6; Glutamate receptor 2; Glutamate receptor 4; Glutamate receptor 3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; G protein-activated inward rectifier potassium channel 1; G protein-activated inward rectifier potassium cha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ablative Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ablative Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-a","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablative Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ablative Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ablative Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ablative Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Ablative Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ethanol","moa":"GABA(A) receptor alpha-1 (GABRA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ablative Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ablative Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ablative Solutions \/ Undisclosed"}]